News - Eli Lilly, Brilinta

Filter

Current filters:

Eli LillyBrilinta

Popular Filters

STEMI guidelines now recommend AstraZeneca's ticagrelor as first-line treatment option

30-08-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) said yesterday that ticagrelor, its oral antiplatelet…

AstraZenecaBrilintaBriliqueCardio-vascularEffientEli LillyPharmaceuticalRegulation

Brazilian acute coronary syndrome drug market set to nearly double to $229 million in 2015

01-12-2011

The acute coronary syndrome (ACS) drug market in Brazil will nearly double from $122 million in 2010…

AstraZenecaBrilintaCardio-vascularEffientEli LillyMarkets & MarketingPharmaceuticalSouth America

China’s acute coronary syndrome drug market forecast to grow to nearly $450 million in 2015

22-11-2011

The acute coronary syndrome (ACS) drug market in China will grow from $326 million in 2010 to $448 million…

Asia-PacificAstraZenecaBrilintaCardio-vascularEffientEli LillyMarkets & MarketingPharmaceuticalPlavixSanofi

Back to top